Is Uveal Melanoma a Hormonally Sensitive Cancer? A Review of the Impact of Sex Hormones and Pregnancy on Uveal Melanoma.
Choroidal melanoma
Pregnancy
Receptor-mediated chemotherapy
Sex hormones
Uveal melanoma
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
06
04
2020
accepted:
21
01
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
5
10
2021
Statut:
ppublish
Résumé
Despite a higher incidence and worse prognosis of uveal melanoma (UM) in men, there have been many case reports of pregnant patients with aggressive UM. This has led researchers to explore the influence of sex hormones and pregnancy on the development and progression of UM and hormones as potential therapeutic targets. A systematic literature review was conducted. More work is needed to elucidate the basis of sex differences in UM incidence and survival. The evaluation of germline Based on review of the literature, UM is not a contraindication to oral contraceptives, hormone replacement therapy, or pregnancy. Globe-sparing radiation can be used as a treatment option for pregnant patients. Due to the presence of ER on a subset of unselected UM, its potential for adjunctive targeted therapy with agents like tamoxifen should be explored. Lessons from cutaneous melanoma regarding tissue ratios of estrogen receptors (ERα:ERβ) should be applied to assess their therapeutic predictive value. In addition, ERRα-targeted therapeutics and LHRH analogs are worthy of further exploration in UM.
Sections du résumé
BACKGROUND
BACKGROUND
Despite a higher incidence and worse prognosis of uveal melanoma (UM) in men, there have been many case reports of pregnant patients with aggressive UM. This has led researchers to explore the influence of sex hormones and pregnancy on the development and progression of UM and hormones as potential therapeutic targets.
SUMMARY
CONCLUSIONS
A systematic literature review was conducted. More work is needed to elucidate the basis of sex differences in UM incidence and survival. The evaluation of germline
KEY MESSAGES
CONCLUSIONS
Based on review of the literature, UM is not a contraindication to oral contraceptives, hormone replacement therapy, or pregnancy. Globe-sparing radiation can be used as a treatment option for pregnant patients. Due to the presence of ER on a subset of unselected UM, its potential for adjunctive targeted therapy with agents like tamoxifen should be explored. Lessons from cutaneous melanoma regarding tissue ratios of estrogen receptors (ERα:ERβ) should be applied to assess their therapeutic predictive value. In addition, ERRα-targeted therapeutics and LHRH analogs are worthy of further exploration in UM.
Identifiants
pubmed: 34604195
doi: 10.1159/000514650
pii: oop-0007-0239
pmc: PMC8443925
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
239-250Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Ophthalmology. 1993 Aug;100(8):1160-5; discussion 1166
pubmed: 8341495
Retin Cases Brief Rep. 2021 Sep 1;15(5):556-563
pubmed: 30640816
Onco Targets Ther. 2018 Feb 22;11:933-941
pubmed: 29503568
Mol Cell Endocrinol. 2015 Dec 5;417:94-102
pubmed: 26415591
JAMA Ophthalmol. 2015 Nov;133(11):1287-94
pubmed: 26402791
Genes Chromosomes Cancer. 2019 Sep;58(9):650-656
pubmed: 30883995
Eur J Pharm Sci. 2018 Oct 15;123:371-376
pubmed: 30076951
J Clin Endocrinol Metab. 2010 Oct;95(10):E224-8
pubmed: 20668045
Ophthalmic Surg Lasers Imaging Retina. 2018 May 1;49(5):364-368
pubmed: 29772048
Am J Ophthalmol. 1966 Nov;62(5):910-3
pubmed: 5928841
Arch Ophthalmol. 1999 Jul;117(7):939-42
pubmed: 10408460
Ophthalmology. 1995 Mar;102(3):431-5
pubmed: 7891981
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S25-32
pubmed: 17259555
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1219-27
pubmed: 17325166
Cancer Res. 1989 Aug 15;49(16):4622-5
pubmed: 2743342
Pigment Cell Res. 1994 Aug;7(4):222-6
pubmed: 7855067
J Fr Ophtalmol. 2003 Mar;26(3):277-80
pubmed: 12746604
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Invest Ophthalmol Vis Sci. 1994 Mar;35(3):826-37
pubmed: 8125745
Invest Ophthalmol Vis Sci. 2013 Jan 23;54(1):652-6
pubmed: 23197684
Ophthalmic Genet. 2015 Jun;36(2):126-31
pubmed: 25687217
Klin Oczna. 2002;104(5-6):395-7
pubmed: 12664489
Int J Dermatol. 2010 Oct;49(10):1194-202
pubmed: 20883410
Med Hypotheses. 1994 Aug;43(2):105-10
pubmed: 7990736
J Biomol Tech. 2018 Jul;29(2):25-38
pubmed: 29805321
Br J Ophthalmol. 1982 Nov;66(11):695-704
pubmed: 7126514
Genomics. 2020 Mar;112(2):1926-1940
pubmed: 31759122
Eur J Ophthalmol. 2006 Nov-Dec;16(6):876-8
pubmed: 17191199
Acta Ophthalmol. 2016 Nov;94(7):e652-e660
pubmed: 27009598
Br J Cancer. 1997;75(6):860-8
pubmed: 9062408
BMC Ophthalmol. 2014 Apr 01;14:42
pubmed: 24685257
Cancer Res. 2018 Oct 1;78(19):5527-5537
pubmed: 30275052
Arch Pathol Lab Med. 2010 Jul;134(7):e48-72
pubmed: 20586616
Expert Opin Investig Drugs. 2012 Jun;21(6):891-9
pubmed: 22577891
Oncotarget. 2020 Jan 14;11(2):175-187
pubmed: 32010430
EMBO J. 1999 Aug 2;18(15):4270-9
pubmed: 10428965
JAMA. 1963 Aug 10;185:542-3
pubmed: 13988958
Ophthalmic Epidemiol. 2013 Dec;20(6):360-8
pubmed: 24229069
Arch Gynecol Obstet. 1996;259(1):1-6
pubmed: 8933922
J Clin Endocrinol Metab. 2004 Mar;89(3):1459-66
pubmed: 15001648
Ophthalmology. 1991 Nov;98(11):1667-73
pubmed: 1800927
Pigment Cell Melanoma Res. 2012 Mar;25(2):182-7
pubmed: 22236444
J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341
pubmed: 30517737
Am J Ophthalmol. 2001 Jun;131(6):788-91
pubmed: 11384577
Melanoma Res. 2000 Aug;10(4):323-30
pubmed: 10985666
Graefes Arch Clin Exp Ophthalmol. 1998 Jun;236(6):415-9
pubmed: 9646085
Neoplasma. 1982;29(6):661-8
pubmed: 6819484
Ophthalmology. 2020 May;127(5):668-678
pubmed: 32081490
Clin Genet. 2016 Mar;89(3):285-94
pubmed: 26096145
J Invest Dermatol. 2003 Sep;121(3):557-63
pubmed: 12925215
J Steroid Biochem Mol Biol. 2019 Jul;191:105352
pubmed: 30954508
J Med Genet. 2011 Dec;48(12):856-9
pubmed: 21941004
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4697-701
pubmed: 18689700
Cancer Causes Control. 2010 Oct;21(10):1625-34
pubmed: 20524054
Acta Ophthalmol. 2011 May;89(3):e290-1
pubmed: 19958288
Am J Obstet Gynecol. 1996 May;174(5):1654-5
pubmed: 9065150
Oncotarget. 2013 Oct;4(10):1721-8
pubmed: 24077773
Trans Am Ophthalmol Soc. 2016 Aug;114:T5
pubmed: 28018010
Am J Ophthalmol. 2021 Apr;224:172-177
pubmed: 33316260
Cancer Res. 1991 Mar 1;51(5):1370-2
pubmed: 1997174
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):1951-4
pubmed: 11481256
Front Endocrinol (Lausanne). 2015 Jul 07;6:93
pubmed: 26217306
Hum Reprod Update. 2014 Jul-Aug;20(4):542-59
pubmed: 24643344